SML0685
Amprenavir
≥98% (HPLC), HIV Protease Inhibitor, powder
别名:
N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3S)-tetrahydro-3-furanyl ester, VX-478
产品名称
Amprenavir, ≥98% (HPLC)
SMILES string
[S](=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]3COCC3)Cc2ccccc2)CC(C)C)c1ccc(cc1)N
InChI
1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
InChI key
YMARZQAQMVYCKC-OEMFJLHTSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +8 to +12°, c = 0.5 in methanol
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
Quality Level
General description
Amprenavir is a second-generation drug derived from hydroxyethylamine sulfonamide.
Biochem/physiol Actions
Amprenavir is an antiretroviral HIV Protease Inhibitor.
Amprenavir is an antiretroviral HIV Protease Inhibitor. It is the active metabolite of fosamprenavir.
Protease inhibition results in inactive and immature virus.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Georgios Leonis et al.
Journal of chemical information and modeling, 53(8), 2141-2153 (2013-07-10)
The emergence of HIV-1 drug-resistant mutations is the major problem against AIDS treatment. We employed molecular dynamics (MD) calculations and free energy (MM-PBSA and thermodynamic integration) analyses on wild-type (WT) and mutated HIV-1 protease (HIV-1 PR) complexes with darunavir, amprenavir
Mélanie Prague et al.
Computer methods and programs in biomedicine, 111(2), 447-458 (2013-06-15)
Models based on ordinary differential equations (ODE) are widespread tools for describing dynamical systems. In biomedical sciences, data from each subject can be sparse making difficult to precisely estimate individual parameters by standard non-linear regression but information can often be
Mary Beth Wire et al.
Clinical pharmacokinetics, 45(2), 137-168 (2006-02-21)
Fosamprenavir is one of the most recently approved HIV-1 protease inhibitors (PIs) and offers reductions in pill number and pill size, and omits the need for food and fluid requirements associated with the earlier-approved HIV-1 PIs. Three fosamprenavir dosage regimens
S Noble et al.
Drugs, 60(6), 1383-1410 (2001-01-11)
The virological/immunological efficacy of amprenavir-containing combination regimens has been evaluated in a small number of clinical trials in patients with HIV infection. Amprenavir plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) was more effective than 2 NRTIs (in treatment-naive patients) or
Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
Polli J W, et al.
Pharmaceutical Research, 16(8), 1206-1212 (1999)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持